Heidelberg Pharma AG Market Cap ($111.58 Million)
Market Cap & Net Worth: Heidelberg Pharma AG (HPHA)
Heidelberg Pharma AG market cap. Heidelberg Pharma AG (F:HPHA) has a market capitalization of $111.58 Million (€95.44 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #18596 globally and #1721 in its home market, demonstrating a -1.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Heidelberg Pharma AG's stock price €2.04 by its total outstanding shares 46784317 (46.78 Million). Also see cash efficiency ratio of Heidelberg Pharma AG for how efficiently the company converts equity into cash flow.
Heidelberg Pharma AG Market Cap History (2015–2026)
Heidelberg Pharma AG market cap history from 2015 to 2026. Data shows growth from $88.88 Million to $111.58 Million (0.30% CAGR). Check latest Heidelberg Pharma AG stock price today for real-time trading data and today's change.
Heidelberg Pharma AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Heidelberg Pharma AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore HPHA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
18.53x
Heidelberg Pharma AG's market cap is 18.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $125.85 Million | $1.36 Million | -$6.39 Million | 92.40x | N/A |
| 2017 | $175.79 Million | $1.90 Million | -$10.97 Million | 92.52x | N/A |
| 2018 | $132.36 Million | $3.67 Million | -$11.67 Million | 36.09x | N/A |
| 2019 | $117.05 Million | $7.31 Million | -$10.15 Million | 16.01x | N/A |
| 2020 | $381.78 Million | $8.49 Million | -$18.37 Million | 44.98x | N/A |
| 2021 | $257.62 Million | $1.75 Million | -$26.14 Million | 147.22x | N/A |
| 2022 | $265.27 Million | $18.51 Million | -$19.70 Million | 14.33x | N/A |
| 2023 | $199.64 Million | $9.86 Million | -$20.35 Million | 20.25x | N/A |
| 2024 | $126.89 Million | $6.85 Million | -$19.38 Million | 18.53x | N/A |
Competitor Companies of HPHA by Market Capitalization
Companies near Heidelberg Pharma AG in the global market cap rankings as of November 4, 2026. Also see HPHA current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Heidelberg Pharma AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Heidelberg Pharma AG (2015–2026)
Market capitalization of Heidelberg Pharma AG from 2015 to today. Between 2015 and today, Heidelberg Pharma AG's market cap moved from $88.88 Million to $ 111.58 Million, with a yearly change of 0.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €111.58 Million | -15.00% |
| 2025 | €131.27 Million | +3.45% |
| 2024 | €126.89 Million | -36.44% |
| 2023 | €199.64 Million | -24.74% |
| 2022 | €265.27 Million | +2.97% |
| 2021 | €257.62 Million | -32.52% |
| 2020 | €381.78 Million | +226.17% |
| 2019 | €117.05 Million | -11.57% |
| 2018 | €132.36 Million | -24.70% |
| 2017 | €175.79 Million | +39.68% |
| 2016 | €125.85 Million | +41.60% |
| 2015 | €88.88 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Heidelberg Pharma AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $111.58 Million USD |
| MoneyControl | $111.58 Million USD |
| MarketWatch | $111.58 Million USD |
| marketcap.company | $111.58 Million USD |
| Reuters | $111.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more